A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Latest Information Update: 07 Mar 2023
At a glance
- Drugs Lirentelimab (Primary)
- Indications Duodenitis; Eosinophilic gastroenteritis
- Focus Therapeutic Use
- Acronyms ENIGMA-SC
- Sponsors Allakos
- 02 Mar 2023 Planned End Date changed from 1 Aug 2024 to 20 Jan 2022.
- 02 Mar 2023 Planned primary completion date changed from 1 Jan 2024 to 20 Jan 2022.
- 02 Mar 2023 Status changed from recruiting to withdrawn prior to enrolment.